Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

Julio Rosenstock, Michaela Diamant, Vanita R. Aroda, Louise Silvestre, Elisabeth Souhami, Tianyue Zhou, Riccardo Perfetti, Vivian Fonseca

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1579-1586
JournalDiabetes Care
Issue number9
Publication statusPublished - Sep 2016

Cite this